Amivantamab is a bispecific antibody used in the treatment of nonsmall cell lung cancer targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) that has known dermatologic adverse effects (dAEs). Here, EGFR is linked to lung cancer.